The therapeutic effect of combination methotrexate with adalimumab in rheumatoid arthritis

Objective To investigate the therapeutic effect of combination adalimumab with methotrexate in rheumatoid arthritis and adverse reactions.Methods Randomly selected from September 2012 to August 2013 active rheumatoid arthritis patients(n =40) for the study,they were divided into treatment group with 25 cases(methotrexate adalimumab) and control group of 15 patients(methotrexate alone).Observe before treatment,12,24 weeks of treatment,the indicators and adverse reactions.Results(1) After 24 weeks of treatment,there are significantly differences between the two groups' overall efficiency(66.0%vs.33.3%,P 0.05),except for joint shortening duration of morning stiffness comparison revealed no significant difference(P 0.05),the treatment group's reduce the rate of tenderness,swelling to reduce rates,VAS score decreased rate better than the control group(P 0.05).(2) Compared with before treatment,after treatment,2group's tender joint count,swollen joint count,morning stiffness and VAS scores at 12 and 24 weeks were improved(P 0.05),in addition to 24 weeks of treatment duration of morning stiffness revealed no significant difference(P 0.05),other indicators of the treatment group improved significantly than in the control group(P 0.05).(3) Compared with before treatment,after treatment,two groups' ESR,CRP,RF at 12 and 24 weeks were improved(P 0.05),and when the 24-week treatment group better than the control group,the difference was statistically significant(P.0.05).(4) 12 and 24 weeks after treatment,the two groups before treatment DAS 28 score were improved(P 0.05),and the treatment group better than the control group(P 0.05).(5) 2,12 and 24 weeks after treatment,sharp score were improvement than before treatment(P 0.05),and at 24 weeks,the treatment group better than the control group(P 0.05).(6)2 groups' incidence of adverse reactions,the treatment group better than the control group(4.0%vs.20.0%,P 0.05).Conclusion Combination of the adalimumab with methotrexate has effect on treatment of rheumatoid arthritis with significantly fewer adverse reactions,can quickly relieve symptoms,worthy of promotion.